

p-PTEN (Ser 380): sc-101788

BACKGROUND

As human tumors progress to advanced stages, one genetic alteration that occurs at high frequency is a loss of heterozygosity (LOH) at chromosome 10q23.31. Mapping of homozygous deletions on this chromosome led to the isolation of the PTEN gene, also designated MMAC1 (for mutated in multiple advanced cancers) and TEP1. This candidate tumor suppressor gene exhibits a high frequency of mutations in human glioblastomas and is also mutated in other cancers, including sporadic brain, breast, kidney and prostate cancers. PTEN has been associated with Cowden disease, an autosomal dominant cancer predisposition syndrome. The PTEN gene product is a putative protein tyrosine phosphatase that is localized to the cytoplasm, and it shares extensive homology with the cytoskeletal proteins tensin and auxilin. Gene transfer studies have indicated that the phosphatase domain of PTEN is essential for growth suppression of glioma cells. PTEN contains 5 major phosphorylation sites and these are all located in the C-terminal 50 amino acid tail region (Ser 370, Ser 380, Thr 382, Thr 383 and Ser 385) and have been implicated in controlling PTEN activity.

REFERENCES

1. Bigner, S.H., et al. 1988. Specific chromosomal abnormalities in malignant human gliomas. *Cancer Res.* 48: 405-411.
2. James, C.D., et al. 1988. Clonal genomic alterations in glioma malignancy stages. *Cancer Res.* 48: 5546-5551.
3. Steck, P.A., et al. 1997. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. *Nat. Genet.* 15: 356-362.
4. Liaw, D., et al. 1997. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. *Nat. Genet.* 16: 64-67.
5. Li, J., et al. 1997. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. *Science* 275: 1943-1947.
6. Nelen, M.R., et al. 1997. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. *Hum. Mol. Genet.* 6: 1383-1387.
7. Furnari, F.B., et al. 1997. Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. *Proc. Natl. Acad. Sci. USA* 94: 12479-12484.

CHROMOSOMAL LOCATION

Genetic locus: PTEN (human) mapping to 10q23.31; Pten (mouse) mapping to 19 C1.

SOURCE

p-PTEN (Ser 380) is a rabbit polyclonal antibody raised against a short amino acid sequence containing Ser 380 phosphorylated PTEN of human origin.

PRODUCT

Each vial contains 100 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

p-PTEN (Ser 380) is recommended for detection of Ser 380 phosphorylated PTEN of mouse, rat and human origin by immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500).


Suitable for use as control antibody for PTEN siRNA (h): sc-29459, PTEN siRNA (m): sc-36326, PTEN shRNA Plasmid (h): sc-29459-SH, PTEN shRNA Plasmid (m): sc-36326-SH, PTEN shRNA (h) Lentiviral Particles: sc-29459-V and PTEN shRNA (m) Lentiviral Particles: sc-36326-V.

Molecular Weight of p-PTEN: 55 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Immunofluorescence: use goat anti-rabbit IgG-FITC: sc-2012 (dilution range: 1:100-1:400) or goat anti-rabbit IgG-TR: sc-2780 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941. 2) Immunohistochemistry: use ImmunoCruz™: sc-2051 or ABC: sc-2018 rabbit IgG Staining Systems.

DATA



p-PTEN (Ser 380): sc-101788. Immunoperoxidase staining of formalin-fixed, paraffin-embedded human breast carcinoma tissue showing cytoplasmic staining.

SELECT PRODUCT CITATIONS

1. Papadakis, E.S., et al. 2011. Axl promotes cutaneous squamous cell carcinoma survival through negative regulation of pro-apoptotic Bcl-2 family members. *J. Invest. Dermatol.* 131: 509-517.

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.



Try **p-PTEN (H-3): sc-377573**, our highly recommended monoclonal alternatives to p-PTEN (Ser 380).